Cancer Research Meeting Calendar EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spitzweg, C.
Right arrow Articles by Morris, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spitzweg, C.
Right arrow Articles by Morris, J. C.
[Cancer Research 60, 6526-6530, November 15, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Treatment of Prostate Cancer by Radioiodine Therapy after Tissue-specific Expression of the Sodium Iodide Symporter1

Christine Spitzweg2, Michael K. O’Connor, Elizabeth R. Bergert, Donald J. Tindall, Charles Y. F. Young and John C. Morris

Departments of Endocrinology [C. S., E. R. B., J. C. M.], Nuclear Medicine [M. K. O.], and Urology [D. J. T., C. Y. F. Y.], Mayo Clinic, Rochester, Minnesota 55905

Causing prostate cancer cells to express functionally active sodium iodide symporter (NIS) by targeted NIS gene transfer might offer the possibility of radioiodine therapy of prostate cancer. Therefore, we investigated radioiodine accumulation and therapeutic effectiveness of 131I in NIS-transfected prostate cancer cells in vitro and in vivo. The human prostatic adenocarcinoma cell line LNCaP was stably transfected with NIScDNA under the control of the prostate-specific antigen promoter. The stably transfected LNCaP cell line NP-1 showed perchlorate-sensitive, androgen-dependent iodide uptake in vitro that resulted in selective killing of these cells by 131I in an in vitro clonogenic assay. Xenografts were established in athymic nude mice and imaged using a gamma camera after i.p. injection of 500 µCi of 123I. In contrast to the NIS-negative control tumors (P-1) which showed no in vivo uptake of 123I, NP-1 tumors accumulated 25–30% of the total 123I administered with a biological half-life of 45 h. In addition, NIS protein expression in LNCaP cell xenografts was confirmed by Western blot analysis and immunohistochemistry. After a single i.p. application of a therapeutic 131I dose (3 mCi), significant tumor reduction was achieved in NP-1 tumors in the therapy group compared with P-1 tumors and tumors in the control group. In conclusion, a therapeutic effect of 131I has been demonstrated in prostate cancer cells after induction of tissue-specific iodide uptake activity by prostate-specific antigen promoter-directed NIS expression in vitro and in vivo. This study demonstrates the potential of NIS as a novel therapeutic gene for nonthyroidal cancers, in particular prostate cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Klutz, V. Russ, M. J. Willhauck, N. Wunderlich, C. Zach, F. J. Gildehaus, B. Goke, E. Wagner, M. Ogris, and C. Spitzweg
Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene
Clin. Cancer Res., October 1, 2009; 15(19): 6079 - 6086.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
S. K. Carlson, K. L. Classic, E. M. Hadac, D. Dingli, C. E. Bender, B. J. Kemp, and S. J. Russell
Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene
Am. J. Roentgenol., January 1, 2009; 192(1): 279 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hingorani, C. L. White, S. Zaidi, A. Merron, I. Peerlinck, M. E. Gore, C. M. Nutting, H. S. Pandha, A. A. Melcher, R. G. Vile, et al.
Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy
Clin. Cancer Res., August 1, 2008; 14(15): 4915 - 4924.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. H. Jeon, Y. Choi, S. O. Yoon, C. W. Kim, and J.-K. Chung
Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy
Mol. Cancer Ther., July 1, 2008; 7(7): 2252 - 2260.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Willhauck, B.-R. Sharif Samani, F.-J. Gildehaus, I. Wolf, R. Senekowitsch-Schmidtke, H.-J. Stark, B. Goke, J. C. Morris, and C. Spitzweg
Application of 188Rhenium as an Alternative Radionuclide for Treatment of Prostate Cancer after Tumor-Specific Sodium Iodide Symporter Gene Expression
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4451 - 4458.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Goel, S. K. Carlson, K. L. Classic, S. Greiner, S. Naik, A. T. Power, J. C. Bell, and S. J. Russell
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV({Delta}51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Blood, October 1, 2007; 110(7): 2342 - 2350.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. I. Kim, J. H. Kang, J.-K. Chung, Y. J. Lee, J. M. Jeong, D. S. Lee, and M. C. Lee
Doxorubicin Enhances the Expression of Transgene Under Control of the CMV Promoter in Anaplastic Thyroid Carcinoma Cells
J. Nucl. Med., September 1, 2007; 48(9): 1553 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. Riesco-Eizaguirre and P. Santisteban
A perspective view of sodium iodide symporter research and its clinical implications.
Eur. J. Endocrinol., October 1, 2006; 155(4): 495 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T Kogai, K Taki, and G A Brent
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Elisei, A. Vivaldi, R. Ciampi, P. Faviana, F. Basolo, F. Santini, C. Traino, F. Pacini, and A. Pinchera
Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2389 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Chen, A. Altmann, W. Mier, H. Eskerski, K. Leotta, L. Guo, R. Zhu, and U. Haberkorn
Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene
J. Nucl. Med., May 1, 2006; 47(5): 854 - 862.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Petrich, L. Quintanilla-Martinez, Z. Korkmaz, E. Samson, H. J. Helmeke, G. J. Meyer, W. H. Knapp, and E. Potter
Effective Cancer Therapy with the {alpha}-Particle Emitter [211At]Astatine in a Mouse Model of Genetically Modified Sodium/Iodide Symporter-Expressing Tumors
Clin. Cancer Res., February 15, 2006; 12(4): 1342 - 1348.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Unterholzner, M. J. Willhauck, N. Cengic, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg
Dexamethasone Stimulation of Retinoic Acid-Induced Sodium Iodide Symporter Expression and Cytotoxicity of 131-I in Breast Cancer Cells
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 69 - 78.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Z. Zhang, Y.-Y. Liu, and S. M. Jhiang
Cell Surface Targeting Accounts for the Difference in Iodide Uptake Activity between Human Na+/I- Symporter and Rat Na+/I- Symporter
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6131 - 6140.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Cengic, C. H. Baker, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg
A Novel Therapeutic Strategy for Medullary Thyroid Cancer Based on Radioiodine Therapy following Tissue-Specific Sodium Iodide Symporter Gene Expression
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4457 - 4464.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Dwyer, E. R. Bergert, M. K. O'Connor, S. J. Gendler, and J. C. Morris
In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter
Clin. Cancer Res., February 15, 2005; 11(4): 1483 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. I. Kim, J.-K. Chung, J. H. Kang, Y. J. Lee, J. H. Shin, H. J. Oh, J. M. Jeong, D. S. Lee, and M. C. Lee
Visualization of Endogenous p53-Mediated Transcription In vivo Using Sodium Iodide Symporter
Clin. Cancer Res., January 1, 2005; 11(1): 123 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Faivre, J. Clerc, R. Gerolami, J. Herve, M. Longuet, B. Liu, J. Roux, F. Moal, M. Perricaudet, and C. Brechot
Long-Term Radioiodine Retention and Regression of Liver Cancer after Sodium Iodide Symporter Gene Transfer in Wistar Rats
Cancer Res., November 1, 2004; 64(21): 8045 - 8051.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Mitrofanova, R. Unfer, N. Vahanian, W. Daniels, E. Roberson, T. Seregina, P. Seth, and C. Link Jr.
Rat Sodium Iodide Symporter for Radioiodide Therapy of Cancer
Clin. Cancer Res., October 15, 2004; 10(20): 6969 - 6976.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Dentice, C. Luongo, A. Elefante, R. Romino, R. Ambrosio, M. Vitale, G. Rossi, G. Fenzi, and D. Salvatore
Transcription Factor Nkx-2.5 Induces Sodium/Iodide Symporter Gene Expression and Participates in Retinoic Acid- and Lactation-Induced Transcription in Mammary Cells
Mol. Cell. Biol., September 15, 2004; 24(18): 7863 - 7877.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. H. Kang, J.-K. Chung, Y. J. Lee, J. H. Shin, J. M. Jeong, D. S. Lee, and M. C. Lee
Establishment of a Human Hepatocellular Carcinoma Cell Line Highly Expressing Sodium Iodide Symporter for Radionuclide Gene Therapy
J. Nucl. Med., September 1, 2004; 45(9): 1571 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. L. Wapnir, M. Goris, A. Yudd, O. Dohan, D. Adelman, K. Nowels, and N. Carrasco
The Na+/I- Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the Thyroid
Clin. Cancer Res., July 1, 2004; 10(13): 4294 - 4302.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
U. Haberkorn, P. Beuter, W. Kubler, H. Eskerski, M. Eisenhut, R. Kinscherf, S. Zitzmann, L. G. Strauss, A. Dimitrakopoulou-Strauss, and A. Altmann
Iodide Kinetics and Dosimetry In Vivo After Transfer of the Human Sodium Iodide Symporter Gene in Rat Thyroid Carcinoma Cells
J. Nucl. Med., May 1, 2004; 45(5): 827 - 833.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. V. Scholz, N. Cengic, B. Goke, J. C. Morris, and C. Spitzweg
Dexamethasone Enhances the Cytotoxic Effect of Radioiodine Therapy in Prostate Cancer Cells Expressing the Sodium Iodide Symporter
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1108 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Barzon, M. Boscaro, and G. Palu
Endocrine Aspects of Cancer Gene Therapy
Endocr. Rev., February 1, 2004; 25(1): 1 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Kogai, Y. Kanamoto, L. H. Che, K. Taki, F. Moatamed, J. J. Schultz, and G. A. Brent
Systemic Retinoic Acid Treatment Induces Sodium/Iodide Symporter Expression and Radioiodide Uptake in Mouse Breast Cancer Models
Cancer Res., January 1, 2004; 64(1): 415 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kakinuma, E. R. Bergert, C. Spitzweg, J. C. Cheville, M. M. Lieber, and J. C. Morris
Probasin Promoter (ARR2PB)-Driven, Prostate-Specific Expression of the Human Sodium Iodide Symporter (h-NIS) for Targeted Radioiodine Therapy of Prostate Cancer
Cancer Res., November 15, 2003; 63(22): 7840 - 7844.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Carlin, G. Akabani, and M. R. Zalutsky
In Vitro Cytotoxicity of 211At-Astatide and 131I-Iodide to Glioma Tumor Cells Expressing the Sodium/Iodide Symporter
J. Nucl. Med., November 1, 2003; 44(11): 1827 - 1838.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Spitzweg, I. V. Scholz, E. R. Bergert, D. J. Tindall, C. Y. F. Young, B. Goke, and J. C. Morris
Retinoic Acid-Induced Stimulation of Sodium Iodide Symporter Expression and Cytotoxicity of Radioiodine in Prostate Cancer Cells
Endocrinology, August 1, 2003; 144(8): 3423 - 3432.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Dingli, R. M. Diaz, E. R. Bergert, M. K. O'Connor, J. C. Morris, and S. J. Russell
Genetically targeted radiotherapy for multiple myeloma
Blood, July 15, 2003; 102(2): 489 - 496.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Braga-Basaria and M. D. Ringel
Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. L. Wapnir, M. van de Rijn, K. Nowels, P. S. Amenta, K. Walton, K. Montgomery, R. S. Greco, O. Dohan, and N. Carrasco
Immunohistochemical Profile of the Sodium/Iodide Symporter in Thyroid, Breast, and Other Carcinomas Using High Density Tissue Microarrays and Conventional Sections
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1880 - 1888.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J.-K. Chung
Sodium Iodide Symporter: Its Role in Nuclear Medicine
J. Nucl. Med., September 1, 2002; 43(9): 1188 - 1200.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. W. A. Smit, J. P. Schroder-van der Elst, M. Karperien, I. Que, M. Stokkel, D. van der Heide, and J. A. Romijn
Iodide Kinetics and Experimental 131I Therapy in a Xenotransplanted Human Sodium-Iodide Symporter-Transfected Human Follicular Thyroid Carcinoma Cell Line
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1247 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Spitzweg, K. J. Harrington, L. A. Pinke, R. G. Vile, and J. C. Morris
The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3327 - 3335.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.